Last reviewed · How we verify
Metabolomics
Metabolomics is a Biologic drug developed by Direction Centrale du Service de Santé des Armées. It is currently in Phase 1 development.
Metabolomics is the scientific study of chemical processes involving metabolites, the small molecule substrates, intermediates, and products of cell metabolism. This field involves the systematic study of the unique chemical fingerprints that specific cellular processes leave behind, specifically examining the small-molecule metabolite profiles.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Metabolomics |
|---|---|
| Sponsor | Direction Centrale du Service de Santé des Armées |
| Modality | Biologic |
| Therapeutic area | Metabolic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nutritional Effects in Cardiovascular Surgery (NA)
- Hepatic Lipid Metabolism-Alcohol Use Disorder
- Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
- Multidimensional Phenotyping Towards Personalized Preventive Nutritional Support for Elderly People (NA)
- Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue
- Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
- USDA Western Human Nutrition Research Center (WHNRC) Cross-Sectional Nutritional Phenotyping Study
- Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metabolomics CI brief — competitive landscape report
- Metabolomics updates RSS · CI watch RSS
- Direction Centrale du Service de Santé des Armées portfolio CI
Frequently asked questions about Metabolomics
What is Metabolomics?
Who makes Metabolomics?
What development phase is Metabolomics in?
Related
- Manufacturer: Direction Centrale du Service de Santé des Armées — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing